Janux Therapeutics Sees Unusually Large Options Volume (NASDAQ:JANX)

by · The Cerbat Gem

Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) saw some unusual options trading on Tuesday. Stock traders acquired 9,510 put options on the stock. This is an increase of 1,493% compared to the typical volume of 597 put options.

Janux Therapeutics Stock Down 49.8%

Shares of NASDAQ JANX traded down $16.92 during midday trading on Tuesday, hitting $17.08. The stock had a trading volume of 8,981,110 shares, compared to its average volume of 988,637. Janux Therapeutics has a 1-year low of $16.70 and a 1-year high of $71.71. The company has a market capitalization of $1.03 billion, a price-to-earnings ratio of -10.18 and a beta of 2.82. The company has a fifty day moving average price of $27.29 and a 200 day moving average price of $25.43.

Janux Therapeutics (NASDAQ:JANX – Get Free Report) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.21. The business had revenue of $10.00 million for the quarter, compared to analyst estimates of $3.07 million. On average, research analysts forecast that Janux Therapeutics will post -1.38 EPS for the current year.

Insider Transactions at Janux Therapeutics

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 3,333 shares of the stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $30.00, for a total transaction of $99,990.00. Following the sale, the insider directly owned 84,974 shares in the company, valued at $2,549,220. This represents a 3.77% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 8.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Janux Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. US Bancorp DE raised its holdings in shares of Janux Therapeutics by 2,402.9% during the 1st quarter. US Bancorp DE now owns 1,727 shares of the company’s stock valued at $47,000 after buying an additional 1,658 shares during the period. Osaic Holdings Inc. raised its stake in shares of Janux Therapeutics by 704.6% during the second quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock valued at $80,000 after purchasing an additional 3,037 shares during the period. Virtus Investment Advisers LLC lifted its position in shares of Janux Therapeutics by 37.9% during the second quarter. Virtus Investment Advisers LLC now owns 3,679 shares of the company’s stock worth $85,000 after purchasing an additional 1,011 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Janux Therapeutics by 175.5% in the second quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock valued at $91,000 after purchasing an additional 2,502 shares during the period. Finally, Ameritas Investment Partners Inc. lifted its holdings in Janux Therapeutics by 25.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,020 shares of the company’s stock worth $93,000 after buying an additional 820 shares in the last quarter. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Truist Financial started coverage on shares of Janux Therapeutics in a research note on Wednesday, September 10th. They set a “buy” rating and a $100.00 target price on the stock. Wall Street Zen raised Janux Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Cantor Fitzgerald reduced their price target on Janux Therapeutics from $200.00 to $150.00 and set an “overweight” rating for the company in a report on Tuesday. Wolfe Research started coverage on shares of Janux Therapeutics in a research report on Tuesday, November 18th. They set a “peer perform” rating for the company. Finally, HC Wainwright lowered their price objective on shares of Janux Therapeutics from $70.00 to $45.00 and set a “buy” rating on the stock in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $70.54.

Check Out Our Latest Research Report on JANX

About Janux Therapeutics

(Get Free Report)

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

Featured Articles